Publications

CNS 2010: Disorders/Therapeutics/ M&A and Partnering Database


The 2010 edition of this incomparable CNS overview has now been released. It comprises two major components:

1) CNS2010 compiles NI Research's comprehensive reviews of all major psychiatric and neurological indications, and the relevant therapeutics programs. All reviews are fully updated and revised. This database provides strategic planners and Business Development professionals with a complete review of the neuro and psychopharmaceutical universe of therapies in development, in a single searchable pdf.
2) MAP: Mergers/Acquisitions/Partnering: Our evaluation reviews the past year of CNS licensing and M&A trends. New for 2010 is a a review of academic CNS programs and licensing patterns, and their access to NIH funding.

There is nothing else like CNS 2010: Disorders/Therapeutics, at any price.


 

439+ pages US$6600

Price for NeuroInvestment subscribers: $5800

Pprice for previous purchasers of the Private CNS Company Review or CNS Disorders/Therapeutics (2007 or 2008): $5000

Startup companies can contact us for pricing options

Download order form

 



NeuroInvestment

Our monthly journal covering the cutting-edge therapies being developed for disorders of the central nervous system, including Alzheimer’s, Parkinson’s, stroke, brain injury, schizophrenia, and depression--and the companies pursuing them. It enjoys worldwide readership and kudoes for its ‘no-holds-barred’ evaluations.

To see some comments from our subscribers.....

$2100 for 1 year subscription

Download order form

Download sample issue (December 2009)




Private CNS Company Review 2010

The 2010 edition of the Private CNS Company Review offers a unique database of information for Business Development professionals evaluating strategic opportunities for inlicensing, outlicensing, M&A, collaboration, and financing. Information and expert opinion regarding private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities. It also assesses the best M&A prospects amongst these private CNS companies. Produced in pdf form for easy searchability. The 2010 edition reviews 102 companies in 146 pages.

 

US$4800

Price for NeuroInvestment subscribers: $4000

Startup companies can contact us for pricing options

Download PCNS 2010 information/order form

     

NeuroInvestment

Private CNS Company Review

CNS Disorders/Therapeutics

760.230.2581